henhaobio
Sign in

bioRxivImmunologyPreprint

The XbnAb Cohort: 305 people with broadly neutralizing antibody activity to HIV-1

Chloé PasiniD, Daniel G. SchmidtiD, Merle SchanziD, Baptiste ElieiD, Nikolas FriedrichiD, Irène A. AbelaiD, Katharina KusejkoiD, Cyrille R. NiklausiD, Michèle Sickmann, Jacqueline WeberiD, Michael HuberiD, Amapola ManriqueiD, Andri RauchiD, Alexandra CalmyiD, Matthias L. CavassiniiD, M Stöckle, Julia NotteriD, Enos BernasconiiD, Dominique L. BrauniD, Huldrych F. GünthardiD, Roger D. KouyosiD, Peter RusertiD, Alexandra TrkolaiD, the Swiss HIV Cohort Study

PDFDOI

Abstract

Broadly neutralizing antibodies (bnAbs) recognizing a diversity of HIV-1 strains are widely thought to be essential for an HIV-1 vaccine. Extensive knowledge on bnAbs has been gained from studying natural HIV infection by following bnAb evolution in individual people with HIV (PWH). However, it remains essential to increase knowledge of bnAb responses in large PWH cohorts to assess the feasibility of inducing bnAb activity by vaccination. To allow systematic analysis, we created the XbnAb cohort, a large bnAb-inducer cohort selected by screening plasma of PWH enrolled in the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI). The XbnAb cohort represents a retrospective, biobank-based cohort comprising data of 305 PWH who developed bnAb activity during HIV-1 infection. Here, we report on the characteristics of the XbnAb cohort and its potential for HIV vaccine research.

Citations
0

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Related papers

Similarity Map
SelectedSame fieldCross-field
THISKorber '26Kreer '22Carter '26Strauli '19Gieselmann '25Skelly '25
73% semantic matchImmunology
Bette Korber, Michael S. Seaman, Nonhlanhla N. Mkhize+13 more·PLoS Pathogens·Apr 23, 2026· 3 citations